ClinicalTrials.gg
TerminatedNCT02012959Updated Sep 26, 2018Results posted

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

A Phase 3 interventional study of Tolvaptan in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 7 sites in 3 countries. Open to participants aged 4 Weeks to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-26.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Issues with participant recruitment \& enrollment which made the trial impossible or highly impracticable. Trial termination was not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
4 Weeks to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
15th of 20
9 · median 55
Started
2015
with 2 others
Phase 3
9 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 14th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 4 Weeks to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

The purpose of this trial was to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent participants with euvolemic or hypervolemic hyponatremia.

03

Conditions studied

  • Hyponatremia

Keywords

  • Hyponatremia
  • Euvolemic
  • Hypervolemic
  • Serum sodium
  • Dilutional hyponatremia
  • Electrolyte abnormality
  • Electrolyte imbalance
  • Metabolic disease
04

Who can participate

Ages eligible
4 Weeks to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥4 weeks (or ≥44 weeks adjusted gestational age) to \<18 years old
  • Participants hospitalized with euvolemic or hypervolemic hyponatremia resistant to initial standard background therapy
  • Persistent euvolemic or hypervolemic hyponatremia defined as being documented as \<130 milliequivalent (mEq)/L and present for at least 48 hours, evidenced by at least 2 serum sodium assessments (12 hours apart)
  • Ability to maintain adequate fluid intake (orally or intravenously)
  • Ability to take oral medications
  • Ability to comply with all requirements of the trial
  • Completion of the trial-specific /assent as age appropriate
  • Ability to commit to remain fully abstinent or practice double-barrier as required by the trial

Exclusion criteria

Exclusion:

  • Evidence of hypovolemia or intravascular volume depletion
  • Serum sodium \<120 mEq/L
  • Use of potent cytochrome P450 3A4 () inhibitors in participants \<12 kilogram (kg) or moderate CYP3A4 inhibitors in participants \<6 kg
  • Lacks free access to water (inability to respond to thirst) or without intensive care unit level fluid monitoring and management
  • History or current diagnosis of nephrotic syndrome
  • Transient hyponatremia likely to resolve
  • Hyperkalemia
  • Estimated \<30 milliliters/minute/1.73 meters squared
  • Acute kidney injury
  • Severe or acute neurological symptoms requiring other intervention
  • Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying serum sodium assessments; urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments; any other treatments for the purpose of increasing serum sodium concurrent with dosing of trial medication
  • Anuria or urinary outflow obstruction, unless participant is/can be catheterized
  • History of and/or idiosyncratic reaction to benzazepine or benzazepine derivatives
  • Psychogenic polydipsia
  • Uncontrolled diabetes mellitus (defined as fasting glucose >300 milligrams/deciliter)
  • Screening liver function values >3 times the
  • Participants who have cirrhosis and meet any of the following conditions: a major GI bleed within the past 6 months, evidence of active bleeding, count \<50,000/microliter, or use of concomitant medications known to increase bleeding risk
  • Hyponatremia due to the result of any medication that can safely be withdrawn or that is most appropriately corrected by alternative therapies
  • History of drug or medication abuse within 3 months prior to screening or current alcohol abuse
  • Participants who require suspension formulation and have a Hereditary Fructose Intolerance
  • Has hyponatremia that is more appropriately corrected by alternative therapies
  • Is pregnant or currently breastfeeding
  • Has any medical condition that could interfere with evaluation of trial objectives or participant safety
  • Has participated in another drug trial in the last 30 days
  • Weighs \<3 kg
  • Unable to swallow tablets, if suspension unavailable
  • Is deemed unsuitable for trial participation in the opinion of the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Tolvaptan Early Withdrawal

    All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment. At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter \[mmol/L\]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days. Discontinued tolvaptan treatment immediately after randomization. All participants were observed up to 14 days post randomization.

    Drug: Tolvaptan

  • Experimental
    Tolvaptan Late Withdrawal

    All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment. At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days. Continued treatment for 2 additional days. All participants were observed up to 14 days post randomization.

    Drug: Tolvaptan

Interventions

06

What researchers measure

Primary outcomes

  1. Change In Serum Sodium Concentration For Responders

    Change in serum sodium concentration (mEq/L) for responders from Day 2 (or Day 2a) at the end of Treatment Phase A (where all participants received tolvaptan) to the end of Treatment Phase B for the Early compared to Late Withdrawal groups is reported. Once a participant was randomized to Treatment Phase B, any additional therapies for the purpose of raising serum sodium, including fluid restriction, were considered rescue therapy. Upon receipt of rescue therapy, a participant's endpoint data was collected and then censored from the efficacy analysis thereafter, unless specified.

    Time frame: Day 2/2a, Day 4

Secondary outcomes

  1. Change In Serum Sodium Concentration During Treatment Phase A

    Change in serum sodium concentration (mEq/L) from baseline to the end of Day 2 (or 2a) during Treatment Phase A for all participants (responders and non-responders) is reported.

    Time frame: Baseline, Day 2/2a

  2. Fluid Balance (Intake Minus Output) During Treatment Phase A

    Every 6 hours and for the 24-hour daily interval on Days 1 and 2 during Treatment Phase A, fluid balance (milliliters \[mL\]) was determined by fluid intake (oral and intravenous) minus urine output. Improved fluid balance would be indicated through the induction of increased urine volume. Fluid balance was monitored per institutional guidelines.

    Time frame: Every 6 hours on Days 1 and 2

07

Results

Posted Aug 28, 2018
Limitations and caveats
Issues with recruitment and enrollment made trial execution highly impracticable. This ultimately led to termination of the trial. The study was not terminated due to safety reasons.

Participant flow

Treatment Phase A
Participant flow — Treatment Phase A
MilestoneTreatment Phase ATreatment Phase B: Responder - Late WithdrawalTreatment Phase B: Responder - Early WithdrawalTreatment Phase B: Non-responder - Study DrugTreatment Phase B: Non-responder - Standard of Care
Started90000
Received at least 1 dose of study drug90000
Completed70000
Not completed20000
Withdrew: Adverse event20000
Treatment Phase B
Participant flow — Treatment Phase B
MilestoneTreatment Phase ATreatment Phase B: Responder - Late WithdrawalTreatment Phase B: Responder - Early WithdrawalTreatment Phase B: Non-responder - Study DrugTreatment Phase B: Non-responder - Standard of Care
Started02311
Received at least 1 dose of study drug02311
Completed02311
Not completed00000

Outcome measures

PrimaryChange In Serum Sodium Concentration For Responders

Change in serum sodium concentration (mEq/L) for responders from Day 2 (or Day 2a) at the end of Treatment Phase A (where all participants received tolvaptan) to the end of Treatment Phase B for the Early compared to Late Withdrawal groups is reported. Once a participant was randomized to Treatment Phase B, any additional therapies for the purpose of raising serum sodium, including fluid restriction, were considered rescue therapy. Upon receipt of rescue therapy, a participant's endpoint data was collected and then censored from the efficacy analysis thereafter, unless specified.

Time frame:
Day 2/2a, Day 4
Reported as:
Mean · mEq/L
Change In Serum Sodium Concentration For Responders
mEq/LResponder - Late WithdrawalResponder - Early Withdrawal
Change In Serum Sodium Concentration For Responders-4.0 ± 4.2-1.0 ± 1.0
SecondaryChange In Serum Sodium Concentration During Treatment Phase A

Change in serum sodium concentration (mEq/L) from baseline to the end of Day 2 (or 2a) during Treatment Phase A for all participants (responders and non-responders) is reported.

Time frame:
Baseline, Day 2/2a
Reported as:
Mean · mEq/L
Change In Serum Sodium Concentration During Treatment Phase A
mEq/LPhase A: All Participants
Day 1: 24 hours Post Dose1 ± 3
Day 2: 24 hours Post Dose3.4 ± 4.8
Day 2a: 24 hours Post Dose2.3 ± 2.1
SecondaryFluid Balance (Intake Minus Output) During Treatment Phase A

Every 6 hours and for the 24-hour daily interval on Days 1 and 2 during Treatment Phase A, fluid balance (milliliters \[mL\]) was determined by fluid intake (oral and intravenous) minus urine output. Improved fluid balance would be indicated through the induction of increased urine volume. Fluid balance was monitored per institutional guidelines.

Time frame:
Every 6 hours on Days 1 and 2
Reported as:
Mean · mL
Fluid Balance (Intake Minus Output) During Treatment Phase A
mLPhase A: All Participants
Day 1: 0-6 hours-1 ± 505
Day 1: 6-12 hours-261 ± 533
Day 1: 12-18 hours-36 ± 253
Day 1: 18-24 hours31 ± 344
Day 1: 0-24 hours-268 ± 849
Day 2: 0-6 hours-101 ± 376
Day 2: 6-12 hours6 ± 513
Day 2: 12-18 hours-45 ± 400
Day 2: 18-24 hours-21 ± 191
Day 2: 0-24 hours-160 ± 733

Adverse events

Collected over From screening through early termination or follow-up phase (14 days postrandomization).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Phase A0/9 (0%)2/9 (22.2%)3/9 (33.3%)
Treatment Phase B: Responder - Late Withdrawal0/2 (0%)1/2 (50%)1/2 (50%)
Treatment Phase B: Responder - Early Withdrawal0/3 (0%)0/3 (0%)2/3 (66.7%)
Treatment Phase B: Non-responder - Study Drug0/1 (0%)1/1 (100%)1/1 (100%)
Treatment Phase B: Non-responder - Standard of Care0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment Phase ATreatment Phase B: Responder - Late WithdrawalTreatment Phase B: Responder - Early WithdrawalTreatment Phase B: Non-responder - Study DrugTreatment Phase B: Non-responder - Standard of Care
Catheter site extravasationGeneral disorders0/90/20/31/10/1
DiarrhoeaGastrointestinal disorders0/91/20/30/10/1
Medical device site haemorrhageGeneral disorders1/90/20/30/10/1
Faecal volume increasedGastrointestinal disorders1/90/20/30/10/1
Most frequent other events
Showing 10 of 14
Most frequent other events
EventTreatment Phase ATreatment Phase B: Responder - Late WithdrawalTreatment Phase B: Responder - Early WithdrawalTreatment Phase B: Non-responder - Study DrugTreatment Phase B: Non-responder - Standard of Care
Blood sodium decreasedInvestigations0/90/20/30/11/1
DyspnoeaRespiratory, thoracic and mediastinal disorders0/90/20/31/10/1
HypoxiaRespiratory, thoracic and mediastinal disorders0/90/20/31/10/1
Nasal inflammationRespiratory, thoracic and mediastinal disorders0/90/20/30/11/1
Fluid overloadMetabolism and nutrition disorders0/90/20/31/10/1
HyperkalaemiaMetabolism and nutrition disorders0/90/20/31/10/1
HyponatraemiaMetabolism and nutrition disorders0/90/20/31/10/1
Nasal congestionRespiratory, thoracic and mediastinal disorders0/91/20/30/10/1
Upper respiratory tract infectionInfections and infestations0/91/20/30/10/1
BradycardiaCardiac disorders0/90/21/30/10/1

Baseline characteristics

Intent-to-treat (ITT) population - Provided following 3 core datasets used for all efficacy analyses: Treatment Phase A; Treatment Phase B responders; Treatment Phase B non-responders.

Age, Continuous
Age, Continuous(years)Treatment Phase A
Mean6.1 ± 5.1
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Phase A
Female3
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Phase A
Hispanic or Latino3
Not Hispanic or Latino5
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Phase A
White6
Black or African American1
American Indian or Alaskan Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Other2
08

Study locations

7 sites
  • Aurora, Colorado 80045, United States
  • Washington, District of Columbia 20010, United States
  • New York, New York 10032, United States
  • Richmond, Virginia 23298-0270, United States
  • Seattle, Washington 98105, United States
  • Rome, 00165, Italy
  • London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Jul 2017, 22 months.

Results were first posted in Aug 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2013
First posted
Dec 17, 2013
StartActual
Sep 22, 2015
Primary completionActual
Jul 24, 2017
CompletionActual
Jul 24, 2017
Results first posted
Aug 28, 2018
Last update
Sep 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02012959
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Sep 22, 2015
Primary completion
Jul 24, 2017
Completion
Jul 24, 2017
Results posted
Aug 28, 2018
Last update
Sep 26, 2018

Study contacts

Global Clinical Development
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion